Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
Maja M. Janas(Alnylam Pharmaceuticals (United States)), Martin A. Maier(Alnylam Pharmaceuticals (United States)), Jayaprakash K. Nair(Alnylam Pharmaceuticals (United States)), Scott Barros(Alnylam Pharmaceuticals (United States)), Lauren P. Blair(Alnylam Pharmaceuticals (United States)), Tracy Zimmermann(Alnylam Pharmaceuticals (United States)), Vasant Jadhav(Alnylam Pharmaceuticals (United States)), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Yuanxin Xu(Nanjing University of Chinese Medicine), Mark K. Schlegel(Alnylam Pharmaceuticals (United States)), Xiumin Liu(Alnylam Pharmaceuticals (United States)), Christopher R. Brown(Alnylam Pharmaceuticals (United States)), Shigeo Matsuda(Alnylam Pharmaceuticals (United States)), Saket Agarwal(Alnylam Pharmaceuticals (United States)), Akin Akinc(Alnylam Pharmaceuticals (United States)), Krishna Aluri(Alnylam Pharmaceuticals (United States)), Akshay Vaishnaw(Alnylam Pharmaceuticals (United States)), Ivan Zlatev(Alnylam Pharmaceuticals (United States)), Muthiah Manoharan(Alnylam Pharmaceuticals (United States)), Kallanthottathil G. Rajeev(Alnylam Pharmaceuticals (United States)), Jing Li(Jinan University), Xuemei Zhang(Central South University), Ju Liu(Liaoning University), Jing‐Tao Wu(Aviation Industry Corporation of China (China)), Peter F. Smith(Alnylam Pharmaceuticals (United States)), Biplab Das(National Institute Of Technology Silchar), Jingxuan Liu(Alnylam Pharmaceuticals (United States)), Chris Tran, Yongfeng Jiang(Alnylam Pharmaceuticals (United States)), Wendell Davis(Alnylam Pharmaceuticals (United States)), Kevin Fitzgerald(Epsilon Systems (United States)), Jessica E. Sutherland(Alnylam Pharmaceuticals (United States)), Klaus Charissé(Alnylam Pharmaceuticals (United States)), Ramesh Indrakanti(Alnylam Pharmaceuticals (United States))
Cited by 78
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
|Angewandte Chemie International Edition|2012|1.2k